658 related articles for article (PubMed ID: 12365013)
21. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
O'Malley DM; Azodi M; Makkenchery A; Tangir J; McAlpine J; Kelly M; Schwartz P; Rutherford T
Gynecol Oncol; 2005 Aug; 98(2):242-8. PubMed ID: 15992916
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
23. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
[TBL] [Abstract][Full Text] [Related]
24. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
[TBL] [Abstract][Full Text] [Related]
25. Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma: a gynecologic oncology group study.
Miller DS; Blessing JA; Lentz SS; McMeekin DS
Cancer; 2003 Oct; 98(8):1664-9. PubMed ID: 14534883
[TBL] [Abstract][Full Text] [Related]
26. Topotecan combined with carboplatin in recurrent epithelial ovarian cancer: results of a single-institutional phase II study.
Kang H; Kim TJ; Lee YY; Choi CH; Lee JW; Bae DS; Kim BG
Gynecol Oncol; 2009 Aug; 114(2):210-4. PubMed ID: 19446320
[TBL] [Abstract][Full Text] [Related]
27. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
[TBL] [Abstract][Full Text] [Related]
28. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
[TBL] [Abstract][Full Text] [Related]
29. Effect of topotecan on serum CA-125 in patients with advanced epithelial ovarian cancer.
Nielsen HA; Nielsen D; Engelholm SA
Gynecol Oncol; 2000 Jun; 77(3):383-8. PubMed ID: 10831346
[TBL] [Abstract][Full Text] [Related]
30. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
Gronlund B; Høgdall C; Hansen HH; Engelholm SA
Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
[TBL] [Abstract][Full Text] [Related]
31. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer.
Gordon AN; Tonda M; Sun S; Rackoff W;
Gynecol Oncol; 2004 Oct; 95(1):1-8. PubMed ID: 15385103
[TBL] [Abstract][Full Text] [Related]
32. European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer.
Ardizzoni A; Manegold C; Debruyne C; Gaafar R; Buchholz E; Smit EF; Lianes P; ten Velde G; Bosquee L; Legrand C; Neumaier C; King K;
Clin Cancer Res; 2003 Jan; 9(1):143-50. PubMed ID: 12538462
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer.
Safra T; Menczer J; Bernstein R; Shpigel S; Inbar MJ; Grisaru D; Golan A; Levy T
Gynecol Oncol; 2007 Apr; 105(1):205-10. PubMed ID: 17239430
[TBL] [Abstract][Full Text] [Related]
34. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
36. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel.
Bolis G; Scarfone G; Tateo S; Mangili G; Villa A; Parazzini F
Gynecol Oncol; 2001 Jan; 80(1):13-5. PubMed ID: 11136562
[TBL] [Abstract][Full Text] [Related]
37. Lack of efficacy of 24-h infusional topotecan in platinum-refractory ovarian cancer: A Gynecologic Oncology Group trial.
Markman M; Blessing JA; DeGeest K; Morgan M; Look KY; Herzog TJ; Rose PG
Gynecol Oncol; 1999 Dec; 75(3):444-6. PubMed ID: 10600304
[TBL] [Abstract][Full Text] [Related]
38. A phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum.
Brown JV; Peters WA; Rettenmaier MA; Karlan BY; Dillman RA; Smith MR; Drescher CW; Micha JP
Gynecol Oncol; 2000 Dec; 79(3):495-8. PubMed ID: 11104627
[TBL] [Abstract][Full Text] [Related]
39. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
40. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
